Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Burning Rock Biotech (BNR) EBT (2019 - 2025)

Burning Rock Biotech has reported EBT over the past 7 years, most recently at -$2.1 million for Q4 2025.

  • For Q4 2025, EBT rose 80.07% year-over-year to -$2.1 million; the TTM value through Dec 2025 reached -$7.6 million, up 83.98%, while the annual FY2025 figure was -$7.7 million, 83.52% up from the prior year.
  • EBT for Q4 2025 was -$2.1 million at Burning Rock Biotech, up from -$2.3 million in the prior quarter.
  • Over five years, EBT peaked at -$1.3 million in Q2 2025 and troughed at -$41.2 million in Q1 2022.
  • A 5-year average of -$20.7 million and a median of -$23.3 million in 2023 define the central range for EBT.
  • Biggest five-year swings in EBT: crashed 247.3% in 2021 and later skyrocketed 91.11% in 2025.
  • Year by year, EBT stood at -$39.6 million in 2021, then rose by 21.51% to -$31.1 million in 2022, then grew by 26.96% to -$22.7 million in 2023, then soared by 54.14% to -$10.4 million in 2024, then skyrocketed by 80.07% to -$2.1 million in 2025.
  • Business Quant data shows EBT for BNR at -$2.1 million in Q4 2025, -$2.3 million in Q3 2025, and -$1.3 million in Q2 2025.